Glycolytic inhibition as a strategy for developing calorie restriction mimetics.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanistic concepts and preclinical targets
PubMed 21167272 · doi:10.1016/j.exger.2010.12.001
What was done
This review evaluates the conceptual and experimental basis of calorie restriction mimetics (CRMs), focusing on upstream glycolytic inhibition compared to downstream molecular targets such as insulin receptor sensitizers, sirtuin activators, and mTOR inhibitors.
What was found
The abstract reports no numerical data. It summarizes that the prototypical glycolytic inhibitor 2-deoxyglucose produces calorie restriction-like phenotypes but causes cardiotoxicity in rats, leading to interest in alternative downstream targets.
Why it matters
It outlines the framework for pharmacological mimetics of dietary restriction to improve healthspan and longevity while highlighting major toxicity hurdles of direct glycolytic inhibition.
Limits
This is a narrative review with no primary empirical human data or systematic search methodology. The discussed interventions rely on preclinical models, and key upstream candidate compounds exhibit limiting toxicities.
Cited by
- supports Chronic administration of 2-deoxyglucose in the diet shortened animal lifespan and caused adverse cardiovascular effects.